Combining D-TACE-HAIC with Envafolimab and Lenvatinib for treating advanced liver cancer

Department of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital

This study is testing a new treatment combining D-TACE-HAIC, Envafolimab, and Lenvatinib to see if it helps people with advanced liver cancer that can't be surgically removed.

Quick facts

• Study type: Observational
• Enrollment: 37 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Fujian Provincial Hospital (Academic / other)
• Drugs / interventions: Envolizumab, Renvastinib, chemotherapy, Envafolimab, Lenvatinib
• Locations: 1 site (Fuzhou, Fujian)
• Trial ID: NCT06643208 on ClinicalTrials.gov

What this trial studies

This clinical trial evaluates the effectiveness and safety of a treatment regimen combining D-TACE-HAIC, Envafolimab, and Lenvatinib for patients with unresectable intrahepatic cholangiocarcinoma. It is a prospective, single-arm, multicenter phase II trial that aims to provide insights into how well this combination can manage the disease. The study will involve patients who meet specific eligibility criteria, including age, liver function, and measurable disease characteristics.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 to 75 with unresectable intrahepatic cholangiocarcinoma and adequate liver function.

Not a fit: Patients who have previously received tumor-related therapies or have severe liver dysfunction may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment approach could offer a new therapeutic option for patients with advanced liver cancer that cannot be surgically removed.

How similar studies have performed: While this approach is innovative, similar studies have shown promise in combining targeted therapies for liver cancers, suggesting potential for success.

Eligibility criteria

Inclusion Criteria:

* 1\. Ages of 18 and 75;
* 2\. Child-Pugh liver function grade: A/B;
* 3\. ECOG score (see annex for scoring standards) : ≤1 score;
* 4\. ICC was confirmed by pathology and evaluated by two senior hepatobiliary surgeons as unresectable for surgery (including multiple intrahepatic lesions, local vascular invasion, local lymph node metastasis, and distant metastasis);
* 5\. According to RECIST 1.1 criteria, the patient has at least one measurable lesion (the CT/MRI scan diameter of the lesion can be measured ≥10mm, and the lesion has not received local treatment such as radiotherapy or freezing);
* 6\. The expected survival time is greater than 3 months;
* 7\. Patients who had not received any tumor-related targeting, immunization, radiotherapy or chemotherapy before enrollment;
* 8\. Functional indexes of vital organs met the following requirements: · Routine blood: absolute neutrophil count ≥1.5×109/L, Hb≥9.0g/L, PLT≥75×109/L; · Liver function: total bilirubin ≤1.5 times the upper limit of normal (ULN) (≤2.5 times ULN after biliary drainage in patients with obstructive jaundice); Alanine aminotransferase (ALT), aspartate aminotransferase (AST)≤ 5x ULN, albumin ≥30g /L; · Renal function: serum creatinine ≤1.5mg/dL, creatinine clearance ≥60ml /min; · Coagulation function: International standardized ratio (INR) and activated partial thromboplastin time (APTT)≤1.5 times ULN;
* 9\. No history of severe arrhythmia or heart failure; No history of severe ventilation dysfunction or severe pulmonary infection;
* 10\. Women of childbearing age should agree to use contraception during the use of medication and for 6 months after the end of medication; Patients who had a negative serum or urine pregnancy test in the 7 days prior to study enrollment and must be non-lactating patients, men should consent to use contraception during the study period and for 6 months after the end of the study period.

Exclusion Criteria:

* 1\. Patients who have previously received other local anti-tumor treatments (such as radiotherapy, radiofrequency ablation, etc.), who are allowed to relapse 6 months after previous surgery, and who are allowed to undergo biliary drainage (including PTCD and biliary stent implantation);
* 2\. History of allergy to gemcitabine, oxaliplatin, Envolizumab, Renvastinib and its components;
* 3\. A history of other malignant tumors within the past 5 years or at the same time, except cured basal cell carcinoma of the skin, cervical carcinoma in situ and thyroid papillary carcinoma;
* 4\. Patients who have previously received an organ transplant or are planning to receive an organ transplant;
* 5\. The presence of any active autoimmune disease or patients with autoimmune disease and expected recurrence (such as interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases and syndromes);
* 6\. History of immune deficiency; The patient is taking immunosuppressants or systemic hormone therapy for immunosuppressive purposes and continues to use it within 2 weeks prior to signing the informed consent;
* 7\. Known hereditary or acquired bleeding (e.g. coagulation disorders) or thrombotic tendencies, e.g. in hemophiliacs; Is currently or recently (within 10 days prior to the start of study therapy) used full dose oral or injectable anticoagulants or thrombolytic agents for therapeutic purposes (prophylactic use of low-dose aspirin, low-molecular weight heparin permitted);
* 8\. Serious infections, such as severe pneumonia, bacteremia, and comorbiditis requiring hospitalization, occurred within 4 weeks prior to the first use of the study drug; Baseline chest imaging findings indicate active lung inflammation, signs and symptoms of infection within 2 weeks prior to the first use of the study drug, or the need for oral or intravenous antibiotic treatment (excluding prophylactic antibiotic use);
* 9\. Patients with mental illness; Have a history of psychotropic substance abuse, alcoholism and drug use;
* 10\. Pregnant or lactating women;
* 11\. Those who, according to the judgment of the researcher, should not participate in this experiment for other reasons;

Where this trial is running

Fuzhou, Fujian

• Fujian Provincial Hospital — Fuzhou, Fujian, China (Recruiting)

Study contacts

• Study coordinator: Maolin Yan, Doctor

Conditions Intrahepatic Cholangiocarcinoma